# DESCRIPTION

## FIELD OF INVENTION

- define novel vaccine consortium

## BACKGROUND AND PRIOR ART OF THE INVENTION

- limitations of current vaccines

## OBJECTIVES OF THE INVENTION

- state objectives of invention

## DETAILED DESCRIPTION OF THE INVENTION

- describe novel formulation of isolated outer membrane vesicles from two thyphoidal Salmonella strains

### Bacterial Strains and Culture Conditions

- describe preparation of OMV antigens from S. typhi C-6953 and S. paratyphi A C-6915

### Preparation of OMVs

- describe preparation of OMVs from two Salmonella enterica strains

### Negative Staining of OMVs and OMV-Secreting Bacteria

- describe negative staining of OMVs and OMV-secreting bacteria

### Animals

- describe animal model used for immunization and challenge studies

### Collection of Serum and Stool

- describe collection of serum and stool samples from immunized and non-immunized mice

### SDS-PAGE and Immunoblot

- describe SDS-PAGE and immunoblot analysis of OMVs

### Dot Blot Assay.

- describe dot blot analysis of LPS from two typhoidal strains

### ELISA

- describe ELISA analysis of immunoglobulins against OMVs and Vi-polysaccharide

### Ex Vivo Studies on Isolated Dendritic Cells

- describe treatment of dendritic cells with bivalent OMV
- describe measurement of cytokines by ELISA
- describe splenocyte re-stimulation assay
- describe measurement of cytokines by ELISA

## The Non-Limiting Advantages are Given Below:

- list advantages of consortium

